Investors Encouraged to Join Altimmune, Inc. Securities Fraud Class Action with Schall Law Firm

Overview of the Class Action Lawsuit Against Altimmune, Inc.

On September 3, 2025, the Schall Law Firm, a prominent name in national shareholder rights litigation, announced a class action lawsuit against Altimmune, Inc. (NASDAQ: ALT). This legal action is based on allegations of violating sections 10(b) and 20(a) of the Securities Exchange Act of 1934 along with Rule 10b-5 as established by the U.S. Securities and Exchange Commission (SEC). Investors who purchased Altimmune securities from August 10, 2023, through June 25, 2025, have been urged to contact the firm before the deadline of October 6, 2025, to understand their options for participation in this lawsuit.

Key Details of the Allegations

The lawsuit arises from claims that Altimmune made false and misleading statements regarding its drug candidate, Pemvidutide. The company promoted the expected performance of this drug in advance of the IMPACT Phase 2B MASH trial results. However, once the trial results were revealed, they indicated a failure to meet the primary endpoint, which was a significant blow to investor confidence.

Despite this failure, Altimmune allegedly downplayed the trial results, suggesting that it anticipated better outcomes from the subsequent Phase 3 trial. This reactive approach led to a distortion in the public's perception of the company's performance and potential, misleading investors throughout the class period.

As a direct consequence of these misleading public statements, once the market became aware of the truth behind the drug candidate's performance, Altimmune's stock experienced a significant downturn, leading to considerable financial losses for its investors. This sharp decline underscores the importance of accurate and transparent information disclosure from publicly traded companies.

Who Should Participate?

Investors who believe they have suffered losses due to their engagement with Altimmune during the specified class period are strongly encouraged to step forward. By joining the class action, they not only stand a chance to recover their financial losses but also contribute to holding the company accountable for its alleged misrepresentations.

Interested shareholders are invited to reach out to Brian Schall, a representative from Schall Law Firm, at their Los Angeles office for a free consultation. The firm emphasizes that, prior to the class being certified, individuals who do not take action may remain absent class members and may miss their opportunity for recovery.

Next Steps and Legal Representation

The Schall Law Firm specializes in securities class action lawsuits and strives to represent investors from across the globe. They are dedicated to advocating for shareholder rights and ensuring that investors have the information necessary to make informed decisions about their legal options.

While this class action is still in preliminary stages and has yet to be certified, potential claimants have until the stated deadline to participate. Investors are encouraged to gather their purchase information for Altimmune securities and reach out for guidance. They can contact the firm either by visiting their website or by calling the office directly.

In conclusion, this case serves as a crucial reminder of the responsibilities that companies like Altimmune hold towards their investors. Transparency and honesty are paramount in maintaining trust within the financial markets, and this lawsuit provides an avenue for affected investors to seek justice.

For more detailed information about the lawsuit and the process of joining the class action, visit Schall Law Firm's website or directly contact their office.